Who are BCMA CAR-T cells's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Elrexfio, ELRANATAMAB, Elrexfio, Bcmaxcd3, Blenrep, Teclistamab (Tec).

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/bcma-car-t-cells.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

BCMA CAR-T cells — Competitive Intelligence Brief

BCMA CAR-T cells (BCMA CAR-T cells) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: CAR-T cell therapy. Area: Oncology.

phase 2 CAR-T cell therapy BCMA Oncology Biologic Live · refreshed every 30 min

Target snapshot

BCMA CAR-T cells (BCMA CAR-T cells) — Chongqing Precision Biotech Co., Ltd. BCMA-targeting CAR-T cells

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
BCMA CAR-T cells TARGET	BCMA CAR-T cells	Chongqing Precision Biotech Co., Ltd	phase 2	CAR-T cell therapy	BCMA
Elrexfio	elranatamab	Pfizer	marketed	Bispecific antibody	BCMA (B-cell maturation antigen) on plasma cells, plasmablasts, and multiple myeloma cells; CD3 on T-cells	2023-01-01
ELRANATAMAB	ELRANATAMAB		marketed		BCMA, CD3	2023-01-01
Elrexfio	Elranatamab	Pfizer	marketed	Bispecific antibody	BCMA (B-cell maturation antigen) on plasma cells, plasmablasts, and multiple myeloma cells; CD3 on T-cells	2023-01-01
Bcmaxcd3	TECLISTAMAB	Johnson & Johnson	marketed		CD3, BCMA	2022-01-01
Blenrep	BELANTAMAB MAFODOTIN	GSK	marketed		BCMA	2020-01-01
Teclistamab (Tec)	Teclistamab (Tec)	University of Heidelberg Medical Center	marketed	Bispecific T-cell engager (BiTE)	CD3 and BCMA

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (CAR-T cell therapy class)

Juno Therapeutics, Inc., a Bristol-Myers Squibb Company · 3 drugs in this class
Chongqing Precision Biotech Co., Ltd · 2 drugs in this class
Guangzhou Women and Children's Medical Center · 2 drugs in this class
Sinocelltech Ltd. · 2 drugs in this class
Gruppo Italiano Malattie EMatologiche dell'Adulto · 1 drug in this class
Guangzhou Bio-gene Technology Co., Ltd · 1 drug in this class
Celyad Oncology SA · 1 drug in this class
Janssen Scientific Affairs, LLC · 1 drug in this class
EdiGene Inc. · 1 drug in this class
Hrain Biotechnology Co., Ltd. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). BCMA CAR-T cells — Competitive Intelligence Brief. https://druglandscape.com/ci/bcma-car-t-cells. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab